期刊文献+

血栓前体蛋白测定在严重脓毒症中的意义及干预治疗对其的影响 被引量:5

Detection of thrombus precursor protein in severe sepsis and intervention therapy of low molecular weight heparins and low dose of urokinase
下载PDF
导出
摘要 目的 评价血浆血栓前体蛋白 (TPP)浓度变化在严重脓毒症中的意义及低分子肝素和小剂量尿激酶干预治疗的效果。方法 应用酶联免疫技术测定 2 5例严重脓毒症患者TPP浓度及PT、APTT、Fib、D -Dimer,并与 10例一般感染者、8例正常对照者进行比较。同时将严重脓毒症患者随机分为治疗组与对照组 ,治疗组给予低分子肝素和小剂量尿激酶及常规治疗 ,对照组仅给予常规治疗 ,比较两组TPP浓度的变化。结果 ①严重脓毒症组TPP浓度与D -Dimer阳性率显著高于一般感染组、正常对照组 (P均 <0 0 5 ) ,而PT、APTT、Fib在三组间差异无显著性 (P均 >0 0 5 )。②治疗组TPP浓度较对照组显著降低 (P均 <0 0 5 ) ,但死亡率无差异 (P >0 0 5 )。结论 TPP测定可反映严重脓毒症的高凝状态 ,且比PT、APTT、Fib、D -Dimer具有更高的敏感性和特异性 ,可作为严重脓毒症早期高凝状态的诊断指标。低分子肝素和小剂量尿激酶的干预治疗可降低TPP的浓度 ,但对预后无影响。 Objective To evaluate the significance of the concentration change of plasma thrombus precursor protein (T PP) in severe sepsis and intervention therapy of low molecular weight heparins and low dose of urokinase. Methods Enzyme linked immunosorbent assay (ELISA) was used in the detection of plasma T PP in 25 patients with severe sepsis group . PT , APTT , Fib , D-Dimer were detected and statistical comparison was carried out in 10 patients with ordinary infection and 8 healthy normal controls. At the same time , severe sepsis group were randomly divided into two groups,the 13 patients in the treated group were treated with low molecular weight heparins and low dose of urokinase and conventional treatment,and the 12 patients in the control group were treated with conventional treatment alone.The concentration change of T PP of two groups were compared. Results ① The concentration of T PP and positive rate of D-Dimer in severe sepsis were obviously higher than those in the ordinary infection group and normal control group (all P<0.05), but levels of PT,APTT,Fib weren't significantly different among three groups. ② The concentration of T PP of the treated group decreased more obviously than that of the control group. Conclusions T PP detection shows hypercoagulable states of severe sepsis and has higher specificity and sensitivity than D-Dimer , PT, APTT , Fib assay .It can be used as a diagnosis parameter for early hypercoagulable states of severe sepsis. Though intervention therapy of low molecular weight heparins and low dose of urokinase can decrease the concentration of T PP , it has no influence on prognosis.
出处 《中国急救医学》 CAS CSCD 北大核心 2005年第1期4-6,共3页 Chinese Journal of Critical Care Medicine
基金 甘肃省自然科学基金暨中青年科技基金项目 (ZS991-A2 3 -0 74-Y)
关键词 血栓前体蛋白 严重脓毒症 肝素 尿激酶 Thrombus precursor protein(T PP) Severe sepsis Heparins Urokinase
  • 相关文献

参考文献9

  • 1王军宇,李春盛.全身炎症反应综合征与代偿性抗炎反应综合征及多器官功能障碍综合征[J].中国急救医学,2003,23(2):97-99. 被引量:16
  • 2袁修学.凝血抑制剂替代疗法:治疗脓毒症的新突破[J].内科急危重症杂志,2002,8(1):46-48. 被引量:9
  • 3陶晓根,承韶辉,赵劲松,高玉华.蛋白C系统与脓毒症[J].中国危重病急救医学,2003,15(1):53-55. 被引量:25
  • 4唐道林,肖献忠.脓毒症及其治疗策略的反思[J].医学与哲学,2004,25(2):14-15. 被引量:3
  • 5Mesters R , Helterbrand J , Utterback BG , et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications [J] . Crit Care Med, 2000,28:2209- 2216.
  • 6Bone RC , Balk RA, Cerra FB, et al . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J]. The ACCP/SCCM College of Chest Physicians Society of Critical Care Medicine. Chest, 1992, 101:1644-1655.
  • 7Scherer RU, Spangenberg P . Procoagulant activity in patients with isolated head trauma[J] . Crit Care Med , 1998 , 26: 149.
  • 8Lacapra S , Arkel YS , Ku DH. The use of thrombus precursor protein ,D-dimer , prothrombin fragment 1 . 2 , and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism[J].Blood Coagul Fibrinolysis , 2000 , 11 : 371-377.
  • 9Paidas MJ , Arkel YS, Ku DH , et al. Markers of the increase in thrombin production in multiple gestion [J]. X Ⅷ ISTH Paris France Abstract, 2001,2262, 2993, 3018.

二级参考文献26

  • 1[1]Hardaway RM. A review of septic shock. Am J Surg, 2000,66: 22.
  • 2[2]Bone RC. Why sepsis trials fail. JAMA, 1996,276:565.
  • 3[3]Esmon CT. Introduction: are natural anticoagulation candidates for modulating the inflarnrnatory response to endotoxin? Blood, 2000, 95:1113.
  • 4[4]Scherer RU, Spangenberg P. P~lant activity in patients withisolated head trauma. Crit Care Med, 1998,26:149.
  • 5[5]Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med, 1999,341:586.
  • 6[6]Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock.Semin Thromb Hemost, 1998,24:33.
  • 7[7]Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med, 2000, 28(Suppl): S77.
  • 8[8]Dickneite G. Antithrombin Ⅲ in animal models of sepsis and organ failure. Semin Thromb Hemost, 1998,24: 61.
  • 9[9]Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl JMed, 2001,344:699.
  • 10[10]Eisele B, Lamy M, ThijsL G, et al. Antithrombin Ⅲ in patients with severe sepsis. A randomized, double-blinded, plaeebo-controlled multicenter trial plus a meta-analysis on all randomized, double-blinded, placebo-controlled trials with Antithrombin Ⅲ in severe sepsis. Intensive Care Med, 1998,24:663.

共引文献42

同被引文献69

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部